Takeda sheds 30 products in emerging markets in $200m deal
October 15, 2019Research and Development
Takeda has sold selected prescription and over the counter products to Acino in the Near East, Middle East and Africa …
New UK Medicines Bill could improve access to new dementia treatments
October 15, 2019Manufacturing and Production
The Government has announced new legislation aimed at providing faster access to medicines, including those treating dementia and Alzheimer’s.The Medicines …
Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine
October 15, 2019Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma
Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …
New £1.2m trial for Parkinson’s patients testing cannabidiol
October 15, 2019Manufacturing and Production
A new clinical trial at King’s College London will investigate the use of cannabidiol (CBD) – a compound found in …
FDA approves Janssen’s Xarelto for blood clot prevention
October 15, 2019Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism
Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …
Reata reports top-line data for omaveloxolone in Freidreich’s ataxia
October 15, 2019Manufacturing and Production
Reata has reported that Part 2 of its mid-stage MOXIe trial of its Nrf2 activator omaveloxolone met its primary endpoint. …
Medical cannabis: On to greener pastures?
October 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma
In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
October 14, 2019Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
Daiichi Sankyo show low CV events and bleeding in NVAF patients on Lixiana
October 14, 2019Sales and Marketing
Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated with …
Shionogi reports positive results for cefiderocol in pneumonia
October 14, 2019Sales and Marketing
Shionogi has reported positive data from a trial of its investigational antibiotic cefiderocol which is already under regulatory review in …
Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
October 14, 2019Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
Three focus areas to accelerate breakthrough drugs to market
October 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing veeva
The number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a …
Biotechnology Innovation Organization Chief to step down after US 2020 elections
October 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biotechnology Innovation Organization, US, biotech, pharma
The Biotechnology Innovation Organization (BIO), the largest trade body representing the world’s biotechnology industry, has revealed that its President and …
Top Ten most popular articles on Pharmafile.com this week
October 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
It’s the end of the week and time for a rundown of our top most popular articles on Pharmafile these …
AbbVie set to receive $330m after exiting Reata deal
October 11, 2019Medical Communications
AbbVie is to receive $330 million after Reata Pharmaceuticals reacquired development, manufacturing and commercialisation rights to a portfolio of Nrf2 …
Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer
October 11, 2019Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma
NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …
Neurolign secures eye diagnostic tech from Neuro Kinetics
October 11, 2019Medical Communications
Neurolign Technologies has acquired US-based eye diagnostic technology firm Neuro Kinetics for an undisclosed sum. Neuro Kinetics is based in …
Bayer UK unveils new Artificial Intelligence ‘LifeHub’
October 10, 2019Research and Development
Bayer has launched LifeHub UK as part of a network of global innovation hubs designed to accelerate and optimise disease …
NICE recommends pentosan polysulfate sodium for NHS treatment of bladder pain syndrome
October 10, 2019Sales and Marketing NHS, NICE, bladder pain syndrome, pentosan polysulfate sodium
NICE has chosen to recommend pentosan polysulfate sodium, it has emerged, for use on the NHS in the treatment of …
Novo Nordisk enters into haemophilia gene therapy collaboration
October 10, 2019Research and Development
Novo Nordisk and bluebird bio have announced they have entered into a three-year research collaboration to jointly develop next-generation in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
